Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Chronic Pancreatitis II: Collaborative Care

Chronic Pancreatitis II: Collaborative Care

The management of chronic pancreatitis is multifaceted, involving a comprehensive approach that includes thorough assessment, diagnostic testing, and a variety of management strategies.
Assessment:

Glucagon-like Receptor Agonists

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...

Acute Pancreatitis I: Introduction

Acute Pancreatitis I: Introduction

Acute pancreatitis is the sudden inflammation of the pancreas caused by the early activation of digestive enzymes, leading to the autodigestion of pancreatic tissue. This results in local inflammation and, in severe cases, systemic complications.EtiologyUnderstanding the underlying causes is crucial, as identifying the etiology guides treatment and anticipates complications. Acute pancreatitis can be triggered by various factors, typically grouped into the following clinical categories.Biliary...

Acute Pancreatitis I: Introduction

Acute Pancreatitis I: Introduction

Pancreatitis is inflammation of the pancreas, an organ located behind the stomach. It can be either acute or chronic.
Acute pancreatitis is characterized by rapid inflammation of the pancreas, often caused by factors like gallstone blockage or excessive alcohol consumption. Chronic pancreatitis, on the other hand, is a slow, progressive inflammation that may result from long-term alcohol abuse, obstructions in the pancreatic duct, or genetic factors.
The causes of acute pancreatitis include:

Pancreatic Juice and Secretion

Pancreatic Juice and Secretion

Pancreatic juice is a clear fluid produced by the pancreas, containing water, salts, sodium bicarbonate, and enzymes vital for digestion in the small intestine. It helps break down large molecules, facilitating nutrient absorption.
When acidic chyme from the stomach enters the duodenum, it triggers the release of secretin, a hormone that prompts pancreatic juice secretion. After a fatty meal, cholecystokinin, another hormone, stimulates gallbladder contraction and enhances enzyme-rich...

Acute Pancreatitis II: Clinical Manifestations and Management

Acute Pancreatitis II: Clinical Manifestations and Management

Acute pancreatitis presents a complex medical emergency characterized by rapid onset inflammation of the pancreas, demanding timely diagnosis and management to prevent complications. The condition primarily manifests through severe upper abdominal pain that often radiates to the back. This pain intensifies following the consumption of fatty foods. Accompanying symptoms such as nausea, vomiting, abdominal distention, fever, dyspnea, cyanosis, and jaundice can vary in intensity but significantly...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Reply to letters to the editor regarding the use of aspirin and mortality due to acute pancreatitis.

Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.]·2026

Same author

Low-dose aspirin use is associated with reduced 30- and 90-day mortality and overall improved outcomes in patients with acute pancreatitis: A multinational multicenter analysis.

Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.]·2025

Same author

An Analysis of the Clinical Burden and Economic Costs of Venous Thromboembolism During Inpatient Admissions for Pancreatic Cancer in the United States.

The American journal of hospice & palliative care·2025

Same author

Multimodal Pancreatic Cancer Detection Using Methylated DNA Biomarkers in Pancreatic Juice and Plasma CA 19-9: A Prospective Multicenter Study.

Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association·2024

Same author

The Determinants of Inpatient Palliative Care Use in Patients With Pancreatic Cancer.

The American journal of hospice & palliative care·2023

Same author

Modified Bedside Index for severity in acute pancreatitis (BISAP) score validation in the national inpatient sample database.

Advances in medical sciences·2023

Search research articles

Related Experiment Video

Updated: Jul 14, 2026

Surface Engineering of Pancreatic Islets with a Heparinized StarPEG Nanocoating

Surface Engineering of Pancreatic Islets with a Heparinized StarPEG Nanocoating

Published on: June 23, 2018

Pancreatic enzyme pharmacotherapy.

Marcus Ferrone¹, Massimo Raimondo, James S Scolapio

¹Department of Clinical Pharmacy, Drug Product Services Laboratory, University of California, San Francisco, California 94118-0613, USA. Ferronem@pharmacy.ucsf.edu

Pharmacotherapy

|June 5, 2007

Summary

Supplemental pancreatic enzyme preparations help patients with pancreatic exocrine deficiency manage steatorrhea and pain. Despite current treatments, many patients still need improved therapies for better outcomes.

Related Experiment Videos

Last Updated: Jul 14, 2026

Surface Engineering of Pancreatic Islets with a Heparinized StarPEG Nanocoating

Surface Engineering of Pancreatic Islets with a Heparinized StarPEG Nanocoating

Published on: June 23, 2018

Area of Science:

Gastroenterology
Pancreatic Diseases
Digestive Health

Background:

Pancreatic exocrine deficiency (PED) affects patients with chronic pancreatitis and cystic fibrosis.
Steatorrhea, characterized by inadequate fat absorption, is a common symptom of PED.
Current treatments aim to improve nutrient absorption and alleviate symptoms through enzyme replacement therapy.

Purpose of the Study:

To review the current landscape of supplemental pancreatic enzyme preparations (PEPs).
To discuss the challenges and limitations of existing PEP treatments.
To highlight the need for optimized therapeutic strategies for patients with PED.

Main Methods:

Review of current clinical practices for PEP administration.
Analysis of standard dosage guidelines for lipase.
Examination of diagnostic approaches for treatment failure.

Main Results:

Standard PEP administration involves lipase 25,000-40,000 units/meal using pH-sensitive microspheres.
Treatment failure necessitates dosage adjustments, compliance monitoring, and differential diagnosis.
Despite available options, a significant number of patients report dissatisfaction with current therapies.

Conclusions:

Optimizing enzyme delivery and formulation is crucial for improving treatment efficacy.
Further research and development are needed to address the unmet needs of patients with PED.
Enhanced PEPs hold promise for better symptom management and improved quality of life.